Arbutus Biopharma Corp (ABUS) Stock Analysis & Investment Frameworks

Arbutus Biopharma Corp (ABUS) stock analysis on Invetso. Review Arbutus Biopharma Corp’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Arbutus Biopharma Corp Company Overview

Arbutus Biopharma Corp Key Financial Metrics

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Arbutus Biopharma Corp Investment Frameworks

Invetso analyzes Arbutus Biopharma Corp (ABUS) across the following frameworks:

Explore More ABUS Research